- Protecting Our Tomorrows: Portraits of Meningococcal Disease showcases the beauty of survivors and raises awareness
TORONTO, April 17, 2014 /CNW/ - To mark World Meningitis Day, world-renowned photographer and UN Ambassador Anne Geddes will unveil her series of 15 meningococcal disease survivor portraits titled Protecting Our Tomorrows: Portraits of Meningococcal Disease.
The collection of inspirational images of meningococcal disease survivors from around the world shows the sudden and profound impact this disease can have on young lives. The image collection eBook will be available for free download through iBooks on April 24.
|What:|| World Meningitis Day
Protecting Our Tomorrows: Portraits of Meningococcal Disease global eBook release
|Who:|| Interviews will be available with speakers:
• Anne Geddes
• Canadian meningitis survivor featured in Protecting Our Tomorrows: Portraits of Meningococcal Disease
• Furakh Mir, Meningitis Relief Canada
• Dr. Ronald Gold, Meningitis Research Foundation Canada
|When:|| Thursday, April 24, 2014
10:30 a.m. to 11:30 a.m.
• Check-in begins at 10:00 a.m.
• One-on-one interviews are available after the unveiling
|Where:|| Art Gallery of Ontario
Baillie Court (3rd floor)
317 Dundas Street West
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2012, the company invested close to $100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. For further information, please consult www.novartis.ca.
Novartis Pharmaceuticals Canada Inc. is a subsidiary of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis Group of Companies offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world.
For more information, please visit http://www.novartis.com.
SOURCE: Novartis Pharmaceuticals Canada Inc.
For further information:
Novartis Media Relations
Manager, External Communications
Novartis Pharmaceuticals Canada Inc.